How One Pharma Company Staffed 3 Vacant Territories in 11 Days

The regional director I'm going to describe here is good at her job. I want to say that upfront because the story doesn't reflect it for a while. She ran a fourteen-rep field force for a specialty pharma company in the Southeast, rare disease focus, and she inherited a staffing problem that turned into three staffing problems in about eight weeks. One planned retirement. Two surprises: one rep took a competitor role, one transferred to medical affairs.

She did what you do. She called her agency contacts. She posted the roles. She pulled an inside sales rep into part-time field coverage on two of the territories while recruiting ran.

I asked her later why she didn't try contractors from the start. She said it didn't occur to her. That's not a bad answer — it just means the contractor option isn't where her mental model for solving this kind of problem starts. For most pharma sales leaders it isn't, because the playbook they've been trained on is built for permanent hires. The thing is, two of her three vacancies weren't permanent-hire problems.

✓

Three Vacant Pharma Territories, One Product Launch Window

Company/Context: Specialty pharma company, rare disease focus, fourteen-rep field force, Southeast US

Situation: Three vacancies in an eight-week window heading into a Q3 launch. Six weeks of traditional recruiting produced one rejected offer and two stalled pipelines. Prescribers in two territories had gone five-plus weeks without rep contact.

What Happened: She engaged MDliaison's contractor marketplace with a brief for each territory — rare disease or adjacent CNS/metabolic background, existing prescriber relationships in the relevant geographies, available within two weeks. Three candidates were presented within 72 hours. Two were engaged in the first week. The third took eleven days, most of that time spent on credentialing at one health system.

Outcome: All three territories had contractor coverage within eleven days. The two week-one reps both hit activity targets in their first thirty days. No key prescriber accounts were lost in the transition. Twelve months later: one contractor converted to a full-time W2 hire. The other two stayed as contractors, by mutual preference.

She told me afterward that the six weeks felt like a sunk cost she couldn't stop investing in. Every week the pipeline wasn't moving, the answer was to push harder on the pipeline — more outreach, more follow-up, more pressure on the agencies. What she didn't do was step back and ask whether the process she was running was the right one for the situation she was actually in.

The rep who took a competitor role: that's a retention failure, not a recruiting gap. The rep who went to medical affairs: structural, possibly temporary, not clearly a permanent backfill need. Both situations needed fast coverage, not thorough evaluation. The permanent-hire process she ran was never going to close that gap cleanly, because it was optimized for a different kind of decision.

The key lesson for me is simple: contractors should not be the "if recruiting fails" option. In launch-sensitive transitions, they are often the primary tool, not the fallback.

Disclaimer: all pricing, timing, and performance figures in this article are directional estimates based on limited samples and should not be treated as guarantees.

The Vacancy Cost That Doesn't Show Up in Recruiting Budgets

Five weeks without rep contact in a rare disease territory isn't a neutral pause. Prescribers who aren't being called on don't hold steady — they make decisions, refer patients somewhere else, start working more closely with whoever is showing up consistently. In rare disease, where reps are sometimes part of the patient identification and referral workflow, a dark territory compounds fast.

I've tracked revenue impact from vacant specialty pharma territories across about fifteen situations. The range is wide and depends heavily on how well-built the prescriber relationships were before the vacancy, how competitive the market is, and how quickly the new rep can reestablish trust. But in early launch windows, I've seen loss periods that took well over a year to recover from. The floor is not zero, and it's usually higher than the cost of trying a contractor arrangement first. Related: The Cost of a Bad Medical Sales Hire.

What the Contractor Model Does and Doesn't Cover in Pharma

No commission-only in pharma. That option is specific to medical device at MDliaison. I bring this up because pharma hiring managers sometimes hear about commission-only from device colleagues and assume it works the same way in their category. It doesn't, and I'd rather you know before you go into a conversation with the wrong expectation.

For pharma, the relevant model is straightforward: pre-vetted contractors, direct management on your side, no setup fee, no long-term minimum. It is faster than a standard permanent-hire cycle, but only if leadership treats onboarding and first-month coaching seriously. The regional director in this case did that. When these engagements fail, the pattern is usually weak management support, not lack of rep talent.

One thing about the eleven-day timeline that's worth being honest about: the credentialing delay on the third territory wasn't unusual. Health system credentialing timelines vary, and rare disease and oncology environments tend to have more complex requirements. If your territories involve health systems with layered credentialing processes, factor in an extra week or two. The twelve-day average is real but it's not guaranteed. Related: 1099 Pharmaceutical Sales Reps Guide.

Need to Cover a Vacant Pharma Territory Fast?

MDliaison's contractor marketplace has pre-vetted specialty pharma sales professionals ready to engage. No setup fees, no minimum contract terms. You manage the rep, we handle sourcing and vetting.

Tell Us About Your Territory

Frequently Asked Questions

Is this case study based on a real company?

Yes. Adjusted for confidentiality, but the timeline, sequence of events, and outcomes reflect a real engagement. Eleven days to field coverage on the third territory is accurate — the credentialing delay is why it wasn't sooner.

What's the honest failure rate on contractor engagements in pharma?

I do not have a defensible percentage, and I would rather be explicit than guess. The failures I have seen usually share one issue: the company under-managed the engagement in the first month, then judged it as if it were a fully ramped W2 role. If active regional support is missing, risk goes up fast.

Does converting a contractor to W2 create legal complications?

There can be classification issues to navigate, and you should have your employment counsel look at the specifics of the engagement before you convert. MDliaison's contractor structure is set up to allow for conversion, but how you've been directing the rep's activities matters. Not a reason to avoid it, but not something to do without a ten-minute call with your HR team first.